RT Journal Article
SR Electronic
T1 Lung function measurements in very low birth weight infants after patent ductus arteriosus ligation
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1303
DO 10.1183/13993003.congress-2016.PA1303
VO 48
IS suppl 60
A1 Payman Barikbin
A1 Hannes Sallmon
A1 Silke Wilitzki
A1 Joachim Photiadis
A1 Christoph Bührer
A1 Petra Koehne
A1 Gerd Schmalisch
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA1303.abstract
AB Objective: The indications and strategies for treatment of patent ductus arteriosus (PDA) are controversial, and the safety and long-term benefits of surgical PDA closure remain uncertain. The aim of this study was to compare the lung function of very low birth weight (VLBW) infants after PDA treatment with a cyclooxygenase inhibitor or surgical ligation.Study design: A total of 114 VLBW infants (birth weight < 1500 g), including 94 infants (82%) with a birth weight < 1000 g, who received treatment for hemodynamically significant PDA (hsPDA) were examined at a median postmenstrual age of 48 weeks. All infants were initially given pharmacological treatment, and 40 infants (35%) required PDA ligation. Lung function testing (LFT) included tidal breathing measurements, measurement of respiratory mechanics assessed by the occlusion test, whole-body plethysmography, SF6 multiple breath washout, forced expiratory flow (V'maxFRC) by the rapid thoracoabdominal compression technique, exhaled NO (FeNO), and arterialized capillary blood gas analysis.Results: On the day of the LFT, the 2 groups had similar postconceptional age and body weight. However, the PDA ligation group was more immature at birth (p < 0.001) and had reduced respiratory compliance (p < 0.001), lower V'maxFRC (p = 0.006), increased airway resistance (Raw) (p < 0.001), and impaired blood gases (p < 0.001). Multivariate analysis showed that PDA surgery was an independent risk factor for increased Raw and reduced respiratory compliance.Conclusions: PDA ligation is associated with impaired lung function in infants with a postmenstrual age of 48 weeks.